Current Research Studies

 A 52-week, randomized, double-blind, double-dummy, placebo- and active- controlled  (Roflumilast, Daliresp® 500µg), parallel group, study to evaluate the efficacy and safety of two doses of  CHF6001 DPI add-on to maintenance triple therapy in subjects with Chronic Obstructive Pulmonary  Disease (COPD) and chronic bronchitis 

 A phase III, 52-week, multinational, multicenter, randomized, double-blind, 2-arm parallel group study comparing efficacy, safety and tolerability of the fixed dose triple combination of beclomethasone dipropionate plus formoterol fumarate plus glycopyrronium bromide (CHF 5993) with the fixed dose dual combination of beclomethasone dipropionate plus formoterol fumarate (CHF 1535), both administered via pMDI in subjects with chronic obstructive pulmonary disease (COPD) 

Randomized, double-blind, placebo-controlled, parallel-group Phase 3 study to evaluate the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab (anti- IL-33 mAb) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD)

 Long-term effect of dupilumab on prevention of lung function decline in patients with uncontrolled moderate-to-severe asthma 

 Dose Ranging Study of SAR443765 Compared With Placebo-control in Adult Participants With Moderate to Severe Asthma (AIRCULES)

A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 52 weeks in participants with severe eosinophilic asthma (EXHALE-2)

A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 24 weeks in participants with eosinophilic asthma (EXHALE-4)